Stockscreener 앱 받기
22.60
2.46%
-0.57
전일 마감가:
$23.17
열려 있는:
$23.19
하루 거래량:
608.66K
Relative Volume:
0.56
시가총액:
$1.70B
수익:
$122.87M
순이익/손실:
$-73.68M
주가수익비율:
-23.05
EPS:
-0.9803
순현금흐름:
$-39.27M
1주 성능:
-0.53%
1개월 성능:
-5.52%
6개월 성능:
+62.12%
1년 성능:
+54.58%
1일 변동 폭
$22.49
$23.52
1주일 범위
$22.07
$23.52
52주 변동 폭
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
명칭
Zymeworks Inc.
전화
604-678-1388
주소
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
22.60 | 1.75B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-10-24 | 재개 | Wells Fargo | Equal Weight |
| 2025-10-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | TD Cowen | Buy |
| 2024-12-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-07 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 재개 | Wells Fargo | Overweight |
| 2023-01-04 | 재확인 | H.C. Wainwright | Neutral |
| 2022-12-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
| 2022-05-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-03-15 | 개시 | Evercore ISI | Outperform |
| 2021-12-10 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 재개 | Guggenheim | Neutral |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-02-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 재개 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-06 | 개시 | SVB Leerink | Outperform |
| 2020-01-10 | 개시 | Wolfe Research | Outperform |
| 2019-12-09 | 개시 | JP Morgan | Neutral |
| 2019-11-25 | 개시 | H.C. Wainwright | Buy |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-30 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 개시 | Stifel | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 개시 | Raymond James | Outperform |
모두보기
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
What is Zymeworks Inc.’s TAM (Total Addressable Market)Long Setup & Precise Buy Zone Identification - mfd.ru
Zymeworks Inc. (ZYME) Stock Analysis: A Biotech Gem With 57% Potential Upside - DirectorsTalk Interviews
Should I average down on Zymeworks Inc. stockJuly 2025 Retail & Low Risk Entry Point Tips - mfd.ru
Is Zymeworks Inc.’s ROE strong enough2025 Short Interest & Precise Trade Entry Recommendations - mfd.ru
Zymeworks Sets Date for 2025 Results and Corporate Update - TipRanks
Zymeworks Inc. Scheduled to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 - GlobeNewswire
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes - MSN
Zymeworks (NASDAQ:ZYME) Trading 1.2% HigherTime to Buy? - MarketBeat
Aug PreEarnings: What is the dividend yield of AKOBMarket Activity Recap & Verified Stock Trade Ideas - baoquankhu1.vn
Zymeworks (ZYME): Biotech under pressure as investors wait for the next big catalyst - AD HOC NEWS
Tejara Capital Ltd Has $1.46 Million Stock Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Zymeworks Inc. (ZYME): Investor Outlook On A Promising Biotech With 59% Upside Potential - DirectorsTalk Interviews
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge - MSN
Zymeworks to Spotlight Pipeline and Portfolio at Series of Major Healthcare Investor Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Aug Volume: Should I set a stop loss on MOFGWeekly Investment Report & Weekly Momentum Picks - baoquankhu1.vn
Assessing Zymeworks (ZYME) Valuation After Major Leadership And Board Reshuffle - Sahm
Stop Loss: Can BHST expand its profit marginsJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Zymeworks Inc. (ZYME) Stock Analysis: Strong Buy Ratings and a Promising 51% Upside Potential - DirectorsTalk Interviews
Analyst Upgrade: Does Zymeworks Inc have strong EBITDA marginsPortfolio Risk Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Does Zymeworks’ HERIZON-GEA-01 Win And Milestone Potential Change The Bull Case For ZYME? - Sahm
Analysts Are Bullish on Top Healthcare Stocks: Zymeworks (ZYME), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN
A Look At Zymeworks (ZYME) Valuation After Positive HERIZON GEA 01 Trial Results And Royalty Milestone Potential - Sahm
New Highs: Can Hippo Holdings Inc lead its sector in growthQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Aug Analyst Calls: What is the earnings history of Zymeworks IncJuly 2025 Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Zymeworks (NYSE:ZYME) Shares Down 5.5%Here's Why - MarketBeat
Hollywood mark, EVP at Zymeworks, sells $138k in shares By Investing.com - Investing.com Nigeria
Zymeworks (NYSE:ZYME) COO Mark Hollywood Sells 6,120 Shares - MarketBeat
Hollywood mark, EVP at Zymeworks, sells $138k in shares - Investing.com
Zymeworks appoints industry veteran Brian Cherry to board By Investing.com - Investing.com Nigeria
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Zymeworks EVP Smith sells shares for $211,090 By Investing.com - Investing.com India
Zymeworks (NYSE:ZYME) EVP Jeffrey Smith Sells 9,310 Shares - MarketBeat
Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 9,560 Shares - MarketBeat
Zymeworks CSO Moore sells $216k in shares By Investing.com - Investing.com Nigeria
Zymeworks EVP Smith sells shares for $211,090 - Investing.com
Zymeworks CSO Moore sells $216k in shares - Investing.com
Insider Selling: Zymeworks (NYSE:ZYME) CEO Sells 30,424 Shares of Stock - MarketBeat
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy - The Globe and Mail
What's Driving Zymeworks Stock Higher? - Nasdaq
Zymeworks Makes Leadership, Board Changes; Begins CFO Search - marketscreener.com
Zymeworks Reshapes Board and Executive Team to Support Next Phase of Growth - TipRanks
Zymeworks appoints industry veteran Brian Cherry to board - Investing.com
Zymeworks Inc. Announces Chief Financial Officer Changes - marketscreener.com
Biotech Zymeworks shakes up its top team as it refocuses strategy - Stock Titan
HERIZON-GEA-01 Trial Highlights Zymeworks’ Path To $440M Milestones And Growth (ZYME) - Seeking Alpha
Zymeworks Inc. (ZYME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):